"Receiving FDA approval on our HPAPI fill line is an exciting milestone for our company, and couldn't have happened without the hard work, hours of prepara...
Announced an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT045...
Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali" or "Cali Biosciences"), a biopharmaceutical company focused on the research and development o...
Recommended dose selected for evaluation of anti-tumor activity in the ongoing Phase 2a portion of the Phase 1/2a study 23andMe Holding Co. (Nasdaq: M...
The project will see the site’s footprint increase by 32,000 square feet (3,000 square meters) to add capacity for the storage and handling of clinic...
Xylyx Bio, a regenerative medicine company developing breakthrough technologies for organ and tissue repair, today announced findings from an independent c...
WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announces that it has added two 2,000 L reactors and a large-sca...
The newly acquired facility and team is in Bentley, a suburb of Perth in Western Australia. It will operate as a Contract Development and Manufacturing Org...
ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for...
-Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced dosing of the first pati...
“2022 was a momentous year for HilleVax where the company achieved many important milestones including the initiation and execution of our Phase 2b c...
AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) ("AnPac Bio," the "Company" or "we"), a company with operations in the United States and ...
SO WHAT: If you purchased Progyny securities you may be entitled to compensation without payment of any out of pocket fees or costs through a continge...
© 2025 Biopharma Boardroom. All Rights Reserved.
